Conclusions
cardiovascular or respiratory organ, critically ill
CRITICALLY ILL
In this randomized clinical trial among critically ill patients hospitalized for COVID-19, an initial strategy of P2Y12 inhibition did not result in a higher probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support. These results do not support the routine use of a P2Y12 inhibitor in critically ill patients hospitalized for COVID-19.